PD-L1 expression on tumor cells evaluated by immunohistochemistry (IHC) was the first identified as a potential indicator of benefit and a “logical” biomarker for the prediction of response to PD-1/PD-L1 ICB in lung cancer. This evidence concerns the gene PDCD1 and neoplasm.